Article Text

other Versions

PDF
Comparison of the Pathvysion and Poseidon HER2 Fish Assays in Measuring HER2 Amplification in Breast Cancer-a Validation Study
  1. Monika Francz1,
  2. Kristof Egervari2,
  3. Laszlo Kardos3,
  4. Judit Toth2,
  5. Zoltan Nemes2,
  6. Janos Szanto2,
  7. Zoltan Szollosi1,*
  1. 1 County Hospital Nyiregyhaza, Hungary;
  2. 2 University of Debrecen Medical and Health Science Center, Hungary;
  3. 3 Kenezy County Hospital Debrecen, Hungary
  1. Correspondence to: Zoltan Szollosi, Department of Pathology, University of Debrecen Medical and Health Science Center, Nagyerdei krt. 98., Debrecen, H-4032, Hungary; szollosi{at}dote.hu

Abstract

Aims: The current study was done as a validation study prior to setting up a clinical HER2 testing service using the new commercial Poseidon HER2 FISH assay. However, it was felt that the experience of the authors of this study may be of interest to other laboratories when considering setting up a HER2 diagnostic facility.

Methods: One hundred and twenty-two patients who had been diagnosed with invasive breast cancer were selected. Immunolabeling with Herceptest, Pathvysion, and Poseidon FISH assays were carried out using tissue microarray blocks.

Results: Concordance correlation coefficients showed near perfect agreement in average HER2 and centromere specific signal counts per cell and in the HER2/CEP17 ratios between the PathVysion and the Poseidon FISH assays. In addition, the Kappa measure showed perfect agreement (Kappa=0.9441, p<0.0001), and - if only 2+ cases were considered - substantial agreement (Kappa=0.7671, p=0.0006) between the two assays. The sensitivity and the specificity of the Poseidon FISH kit were calculated to be 95.2% and 100%, respectively, whereas the positive (PPV) and negative predictive values (NPV) were 100% and 99%. With regard to the ability to presume HER2 polysomy, the Poseidon FISH kit had a sensitivity of 93.3% and a specificity of 99.1% with a PPV and NPV of 93.3% and 99.1%, respectively, as assessed with PathVysion classification as reference.

Conclusions: Statistical analysis confirmed that the two FISH assays are comparable in terms of detection of HER2 gene amplification. Proceeding from these findings, the genetic diagnoses obtained with the Poseidon kit can be considered as valuable as the results from the Food and Drug Administration (FDA) approved PathVysion assay, and propose its utilization in routine HER2 diagnostics.

Statistics from Altmetric.com

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.